Cargando…

Development of a novel immune-related genes prognostic signature for osteosarcoma

Immune-related genes (IRGs) are responsible for osteosarcoma (OS) initiation and development. We aimed to develop an optimal IRGs-based signature to assess of OS prognosis. Sample gene expression profiles and clinical information were downloaded from the Therapeutically Applicable Research to Genera...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zuo-long, Deng, Ya-jun, Zhang, Guang-zhi, Ren, En-hui, Yuan, Wen-hua, Xie, Qi-qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591524/
https://www.ncbi.nlm.nih.gov/pubmed/33110201
http://dx.doi.org/10.1038/s41598-020-75573-w
_version_ 1783601013478916096
author Wu, Zuo-long
Deng, Ya-jun
Zhang, Guang-zhi
Ren, En-hui
Yuan, Wen-hua
Xie, Qi-qi
author_facet Wu, Zuo-long
Deng, Ya-jun
Zhang, Guang-zhi
Ren, En-hui
Yuan, Wen-hua
Xie, Qi-qi
author_sort Wu, Zuo-long
collection PubMed
description Immune-related genes (IRGs) are responsible for osteosarcoma (OS) initiation and development. We aimed to develop an optimal IRGs-based signature to assess of OS prognosis. Sample gene expression profiles and clinical information were downloaded from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) and Genotype-Tissue Expression (GTEx) databases. IRGs were obtained from the ImmPort database. R software was used to screen differentially expressed IRGs (DEIRGs) and functional correlation analysis. DEIRGs were analyzed by univariate Cox regression and iterative LASSO Cox regression analysis to develop an optimal prognostic signature, and the signature was further verified by independent cohort (GSE39055) and clinical correlation analysis. The analyses yielded 604 DEIRGs and 10 hub IRGs. A prognostic signature consisting of 13 IRGs was constructed, which strikingly correlated with OS overall survival and distant metastasis (p < 0.05, p < 0.01), and clinical subgroup showed that the signature’s prognostic ability was independent of clinicopathological factors. Univariate and multivariate Cox regression analyses also supported its prognostic value. In conclusion, we developed an IRGs signature that is a prognostic indicator in OS patients, and the signature might serve as potential prognostic indicator to identify outcome of OS and facilitate personalized management of the high-risk patients.
format Online
Article
Text
id pubmed-7591524
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-75915242020-10-28 Development of a novel immune-related genes prognostic signature for osteosarcoma Wu, Zuo-long Deng, Ya-jun Zhang, Guang-zhi Ren, En-hui Yuan, Wen-hua Xie, Qi-qi Sci Rep Article Immune-related genes (IRGs) are responsible for osteosarcoma (OS) initiation and development. We aimed to develop an optimal IRGs-based signature to assess of OS prognosis. Sample gene expression profiles and clinical information were downloaded from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) and Genotype-Tissue Expression (GTEx) databases. IRGs were obtained from the ImmPort database. R software was used to screen differentially expressed IRGs (DEIRGs) and functional correlation analysis. DEIRGs were analyzed by univariate Cox regression and iterative LASSO Cox regression analysis to develop an optimal prognostic signature, and the signature was further verified by independent cohort (GSE39055) and clinical correlation analysis. The analyses yielded 604 DEIRGs and 10 hub IRGs. A prognostic signature consisting of 13 IRGs was constructed, which strikingly correlated with OS overall survival and distant metastasis (p < 0.05, p < 0.01), and clinical subgroup showed that the signature’s prognostic ability was independent of clinicopathological factors. Univariate and multivariate Cox regression analyses also supported its prognostic value. In conclusion, we developed an IRGs signature that is a prognostic indicator in OS patients, and the signature might serve as potential prognostic indicator to identify outcome of OS and facilitate personalized management of the high-risk patients. Nature Publishing Group UK 2020-10-27 /pmc/articles/PMC7591524/ /pubmed/33110201 http://dx.doi.org/10.1038/s41598-020-75573-w Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Wu, Zuo-long
Deng, Ya-jun
Zhang, Guang-zhi
Ren, En-hui
Yuan, Wen-hua
Xie, Qi-qi
Development of a novel immune-related genes prognostic signature for osteosarcoma
title Development of a novel immune-related genes prognostic signature for osteosarcoma
title_full Development of a novel immune-related genes prognostic signature for osteosarcoma
title_fullStr Development of a novel immune-related genes prognostic signature for osteosarcoma
title_full_unstemmed Development of a novel immune-related genes prognostic signature for osteosarcoma
title_short Development of a novel immune-related genes prognostic signature for osteosarcoma
title_sort development of a novel immune-related genes prognostic signature for osteosarcoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591524/
https://www.ncbi.nlm.nih.gov/pubmed/33110201
http://dx.doi.org/10.1038/s41598-020-75573-w
work_keys_str_mv AT wuzuolong developmentofanovelimmunerelatedgenesprognosticsignatureforosteosarcoma
AT dengyajun developmentofanovelimmunerelatedgenesprognosticsignatureforosteosarcoma
AT zhangguangzhi developmentofanovelimmunerelatedgenesprognosticsignatureforosteosarcoma
AT renenhui developmentofanovelimmunerelatedgenesprognosticsignatureforosteosarcoma
AT yuanwenhua developmentofanovelimmunerelatedgenesprognosticsignatureforosteosarcoma
AT xieqiqi developmentofanovelimmunerelatedgenesprognosticsignatureforosteosarcoma